State of Wyoming Acquires New Shares in Prestige Consumer Healthcare Inc. $PBH

State of Wyoming acquired a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 13,100 shares of the company’s stock, valued at approximately $619,000.

Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth about $29,000. Versant Capital Management Inc raised its position in shares of Prestige Consumer Healthcare by 47.9% during the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after purchasing an additional 235 shares during the period. Torren Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $35,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $51.51 on Monday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 14.43, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The stock’s 50-day moving average is $49.46 and its 200-day moving average is $55.51. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same period in the prior year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).